Intuitive Surgical, Inc. (ISRG) Stock Analysis
Is ISRG a good investment?
Intuitive Surgical, Inc. (ISRG) has a Plutrex AI rating of 70.0/100 as of November 13, 2026, indicating a Buy consensus. The stock is not classified as halal-compliant. Key strength: Unrivaled profitability moat: gross margin 67.2% (+46% vs. industry), operating margin 31.7% (+140% vs. industry), net margin 25.5% (+264% vs. industry), all with zero debt — a combination no peer can match; da Vinci 5 driving 546 system placements last quarter with 84% recurring revenue creating durable, predictable cash flows. Main concern: Valuation remains severely stretched: P/E 53.42x on 10.9% next-year EPS growth implies forward PEG ~4.9x; standalone DCF fair value $280-$320 implies 27-37% downside; analyst consensus target $493.11 provides only 12.1% upside — insufficient margin of safety at this multiple; instrument price reductions creating 3-5% near-term revenue headwind could trigger guidance miss and 15-25% multiple compression at 53x earnings.
Investment Summary
ISRG is a world-class surgical robotics business trading at a persistent valuation premium that continues to limit new entry appeal. The stock has pulled back modestly from $448.76 to $439.89 (-2.0%) since our prior report, and P/E has contracted slightly from 54.3x to 53.42x — directionally correct but not materially sufficient to change the investment thesis. Core financials remain exceptional: gross margin 67.2% (vs. industry 45.9%), operating margin 31.7% (vs. industry 13.2%), net margin 25.5% (vs. industry 7.0%), zero debt vs. industry D/E of 0.51, $4.04B cash, and $3.60B annual FCF. The da Vinci 5 platform is gaining commercial traction with 546 systems placed last quarter per headlines, and 84% recurring revenue provides revenue floor visibility. However, the valuation problem persists: P/E of 53.42x on next-year EPS growth of only 10.9% implies a forward PEG of ~4.9x — severely stretched. The $450M litigation settlement (Headline: 'ISRG Agrees to $450M Settlement') is a meaningful one-time cash outflow but manageable against $4.04B cash. News sentiment hit 94.6/100 with 8 of 9 articles positive, but good news is largely priced in at 53x earnings. For existing holders: HOLD. For new buyers: wait for entry zone $405-$425.
Key Strengths
- Unrivaled profitability moat: gross margin 67.2% (+46% vs. industry), operating margin 31.7% (+140% vs. industry), net margin 25.5% (+264% vs. industry), all with zero debt — a combination no peer can match; da Vinci 5 driving 546 system placements last quarter with 84% recurring revenue creating durable, predictable cash flows
- Fortress balance sheet: $4.04B cash + $3.60B annual FCF with D/E = 0 vs. industry 0.51 — the $450M litigation settlement is fully absorbable without stress, and self-funded growth in da Vinci 5, Ion GI platform, and ASC expansion requires zero capital markets access
- PEG of 3.29x is 32.4% BELOW industry average of 4.86x — despite the absolute P/E premium of 53.42x, ISRG is cheaper per unit of growth than the typical peer; 5-year EPS CAGR of 16.3% vs. industry 12.4% and revenue growth of 21.7% vs. industry 12.5% validate the structural growth advantage
Key Concerns
- Valuation remains severely stretched: P/E 53.42x on 10.9% next-year EPS growth implies forward PEG ~4.9x; standalone DCF fair value $280-$320 implies 27-37% downside; analyst consensus target $493.11 provides only 12.1% upside — insufficient margin of safety at this multiple; instrument price reductions creating 3-5% near-term revenue headwind could trigger guidance miss and 15-25% multiple compression at 53x earnings
- EPS deceleration from 29.3% historical to 10.9% next year (62% reduction in earnings momentum) combined with trailing GAAP earnings growth of -23.6% (vs. industry +127.2%) is unexplained and potentially masks structural cost pressures; $450M litigation settlement while manageable is a signal of competitive/IP challenges ahead from rivals entering surgical robotics space
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
ISRG's fundamentals remain at the apex of the medical device sector. Profitability: Gross margin 67.2% vs. industry 45.9% (+46.4% premium), operating margin 31.7% vs. industry 13.2% (+140% premium), net margin 25.5% vs. industry 7.0% (+264% premium), ROE 18.0% vs. industry 7.4% (+143% premium) — all achieved with zero financial leverage, making the ROE even more impressive. Balance sheet: D/E = 0 vs. industry 0.51, $4.04B cash, $3.60B annual FCF — fortress class. Growth: Revenue growing 21.7% (vs. industry 12.5%), but next-year EPS growth decelerating to 10.9% from historical 29.3% — a 62% deceleration in earnings momentum. 5-year EPS CAGR projected at 16.3% vs. industry 12.4%. Valuation: P/E 53.42x vs. industry 41.6x (+28% premium), PEG 3.29x vs. industry 4.86x (32% discount on growth-adjusted basis — the most important relative valuation data point). On standalone DCF at $3.6B FCF, 16.3% 5-year growth, 8% terminal, 10% discount rate, intrinsic value approximates $280-$320 — implying 27-37% downside to intrinsic value from current prices. The stock demands near-perfect execution, and instrument price reductions creating a 3-5% revenue headwind remain a near-term risk at this multiple.
News Sentiment
Intuitive Surgical is riding a wave of optimism as its next-generation da Vinci 5 robotic surgery system gains real traction in hospitals — but investors are wrestling with whether the stock's lofty price tag still makes sense. The company placed 546 da Vinci systems in just one quarter, a headline-grabbing number that Wall Street is still debating (Headline: 'Intuitive Surgical Placed 546 da Vinci Systems Last Quarter. Why Wall Street's S...'). Some analysts are skeptical the placement pace can sustain the premium valuation, while others argue the growing installed base of systems locks in years of profitable instrument and maintenance revenue. The stock has gained 7.8% over six months, prompting the question everyone is asking: can it keep going? (Headline: 'ISRG Gains 7.8% in 6 Months: Will the Share Price Recovery Continue?'). One significant cloud on the horizon: ISRG just agreed to a $450 million legal settlement (Headline: 'ISRG Agrees to $450M Settlement: What Does It Mean for Investors?'), a hefty sum that underscores the competitive and legal pressures building around its dominant market position. Still, with $4 billion in cash, the settlement barely dents ISRG's financial fortress. Some analysts have trimmed their price targets while remaining bullish long-term (Headline: 'Intuitive Surgical: Why I Remain Bullish Despite Cutting My Price Target'), and during recent Nasdaq turbulence, ISRG was highlighted as a proven winner worth holding through volatility (Headline: 'Nasdaq-100 Correction: 2 Proven Winners That Can Buck Historic Volatility'). The bottom line: exceptional business, premium price.
Risk Assessment
PRIMARY RISK: Multiple compression. At P/E 53.42x on 10.9% next-year EPS growth, any guidance miss, procedure volume shortfall, or macro-driven multiple de-rating could trigger 15-25% drawdown rapidly. The instrument price reductions management signaled represent a concrete 3-5% revenue headwind that is not fully absorbed in consensus estimates. SECONDARY RISK: Competitive entry. The $450M litigation settlement (Headline: 'ISRG Agrees to $450M Settlement') signals IP challenges and competitors are increasingly pressuring ISRG's moat — though the moat remains durable for now. MITIGATION: Entry at $405-$425 (P/E 47.0-49.4x) provides ~11-13% buffer versus current price, reducing multiple compression exposure. Stop at $382 (P/E ~44.4x, near industry average with ISRG deserving modest premium) limits downside to -7.9% from entry midpoint. Position size 3.5% of portfolio acknowledges quality but respects valuation risk. Time horizon 12-18 months allows da Vinci 5 adoption curve to validate or invalidate the growth reacceleration thesis.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is ISRG a halal stock?
No, Intuitive Surgical, Inc. (ISRG) is currently not classified as halal by AAOIFI criteria.
What is Plutrex's AI rating for ISRG?
Intuitive Surgical, Inc. (ISRG) has a Plutrex AI rating of 70.0/100 with a Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is ISRG a good investment?
According to Plutrex AI, ISRG has a Buy rating (70.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in ISRG?
US stocks like ISRG can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. ElBarake provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in ISRG?
Plutrex AI identifies the main risks for ISRG by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.